Schering Gains HCV Retreatment Indication For Pegintron/Rebetol In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Commission clears the combination to retreat adults whose prior treatment with interferon alpha and ribavirin did not result in a sustained response.
You may also be interested in...
Roche Polymerase Inhibitor Shows Promise In Phase II
Ahead of AASLD, Roche’s Senior Medical Director Thommes discusses the firm’s hepatitis C pipeline with “The Pink Sheet” DAILY.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.